shares drug suspension
shares elan biogen idec plunged suspended multiple sclerosis drug tysabri patient
york stock exchange shares elan partner biogen idec nervous disease suspected condition cited tysabri avonex biogen idec existing multiple sclerosis drug rare condition progressive multifocal leukoencephalopathy pml patients tysabri avonex tysabri approved tipped multiple sclerosis treatment
clinical investigators evaluate patients consult experts pml outcome evaluations determine dosing clinical trials commercial availability
biogen idec faced rivals avonex elan irish stock exchange receive elan bankruptcy rebuilding increasing tysabri ian hunter goodbody stockbrokers dublin elan finished biogen fell
shares pharmaceutical phytopharm closed pence stock exchange partner pull experimental alzheimer disease treatment phytopharm yamanouchi pharmaceutical licensing agreement prompting reserves
